Founding Director, Neurobiology Research Laboratory (NBRL)
Kansas City VA Medical Center 1976-2010
Departments of Neurology, Pharmacology, and Molecular and Integrative Physiology
University of Kansas Medical Center
Dr. Festoff's clinical interests are in neuromuscular disorders, specifically amyotrophic lateral sclerosis (ALS) and neuroimmune neuropathies, such as monoclonal gammaopathy of uncertain significance (MGUS) neuropathy and chronic inflammatory demyelinating neuropathy (CIDP).
He has done extensive translational research in neurology/neurobiology focusing on neurodegeneration in Alzheimer's Disease (AD), ALS, and in animal models of acute spinal cord injury (SCI) as well as traumatic brain injury (TBI). His current projects include those to reverse neuronal death in aging and in trauma, especially mild TBI (concussion), and to "harness" neuroinflammation in CNS trauma. Therapeutic target development in TBI and its evolution to AD, ALS or chronic traumatic encephalopathy (CTE) involves understanding the mechanisms for disruption of the blood brain barrier (BBB) in these conditions. Following his retirement from the Kansas City Veterans Affairs Medical Center (KCVAMC) in 2010 he has founded a biotherapeutic and diagnostic biotechnology company.
Barry W. Festoff, M.D.